BSECompany Update12 Oct 2026 · 12 Oct 2026, 05:06 pm

Certificate pursuant to Regulation 74 (5) of SEBI regulation, 2018.

Kabra Drugs Ltd · 524322

✦ AI SummaryRegulatory

Kabra Drugs Ltd has submitted a certificate confirming compliance with Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September 2026.

Analysis Scores

Earnings Impact1/10

Growth Catalyst1/10

Governance Concern1/10

Regulatory Risk2/10

Balance Sheet Risk1/10

Liquidity Impact1/10

Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

Full Announcement

Kabra Drugs Ltd - 524322 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Attachments (1)

📄

a310411c-76ab-4b22-bab6-ff87eefad94c.pdf

pdf

Download →

View document text

Date: 12th October 2026 BSE Limited Phiroze Jeejeebhoy Towers 21st Floor, Dalal Street Mumbai – 400 001 BSE Scrip Code: 524322 Dear Sir/Madam, Sub: Certificate pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. We enclose herewith a certificate issued by Skyline Financial Services Pvt Ltd, Registrar and Share Transfer Agent of the Company confirming the compliance under the Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026. This is for your information & records. Thanking you, Yours sincerely, For Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) Nanjappan Aravind Managing Director DIN: 01895602